Last reviewed · How we verify
Misotac® Sigma Pharmaceutical Industries
Misoprostol is a prostaglandin E1 analogue that protects the gastric mucosa and reduces acid secretion.
Misoprostol is a prostaglandin E1 analogue that protects the gastric mucosa and reduces acid secretion. Used for Prevention of NSAID-induced gastric ulcers, Treatment of gastric and duodenal ulcers.
At a glance
| Generic name | Misotac® Sigma Pharmaceutical Industries |
|---|---|
| Also known as | Misotac (Misoprostol) |
| Sponsor | Ain Shams University |
| Drug class | Prostaglandin analogue |
| Target | Prostaglandin E1 receptor (EP receptor) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Misoprostol binds to prostaglandin receptors on gastric mucosa cells, enhancing mucus and bicarbonate secretion while simultaneously reducing gastric acid production. It is commonly used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers and to promote gastric healing in existing ulcer disease.
Approved indications
- Prevention of NSAID-induced gastric ulcers
- Treatment of gastric and duodenal ulcers
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Flatulence
Key clinical trials
- Sublingual Misoprostol Versus No Cervical Priming Before Hysteroscopic Resection of Symptomatic Uterine Niches (NA)
- Methods Decreasing Bleeding in Open Myomectomy (PHASE4)
- Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time. (PHASE2, PHASE3)
- Vaginal Misoprostol Before Intrauterine Contraceptive Device Insertion (PHASE3)
- Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor (PHASE3)
- Sublingual Misoprostol & Isoflurane During Caesarean Section (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: